Omnipaque (Iohexol)

Iohexol, the active ingredient in Omnipaque, is a non‑ionic low‑osmolality iodinated contrast medium presented as a sterile injectable solution for intravascular use. It enhances radiographic visualization of vascular structures and organ systems during diagnostic imaging procedures. GNH USA supplies Omnipaque as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

GNH USA supplies Omnipaque as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Omnipaque is employed in radiographic procedures that require enhanced contrast of vascular and tissue structures.

- Angiography: Improves visualization of blood vessels for diagnostic assessment. - Computed Tomography (CT): Provides high‑contrast images of organs and soft tissues. - Intravenous urography: Enhances delineation of the urinary tract during X‑ray studies. - Myelography: Facilitates clear imaging of the spinal canal and nerve roots. - Venography: Highlights veins to detect thrombosis or obstruction. - Endovascular interventions: Assists in real‑time imaging guidance during minimally invasive procedures.

Adverse reactions to Omnipaque may vary in frequency and severity.

Common Side Effects: - Warmth or flushing sensation at the injection site - Mild nausea or vomiting - Transient headache - Temporary metallic taste - Mild itching or rash - Slight increase in serum creatinine (usually reversible)

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis) - Acute kidney injury, especially in patients with pre‑existing renal impairment - Cardiovascular collapse - Pulmonary edema - Severe hypotension - Persistent neurological deficits (rare)

Before using Omnipaque, clinicians should assess patient risk factors and follow recommended preparation guidelines.

- Renal function assessment: Evaluate baseline creatinine and eGFR, especially in patients with known kidney disease. - Allergy history: Review prior reactions to iodinated contrast agents or iodine‑containing substances. - Hydration status: Ensure adequate fluid intake before and after administration to reduce nephrotoxicity risk. - Thyroid monitoring: Be aware of potential iodine‑induced thyroid dysfunction in susceptible individuals. - Concomitant nephrotoxic drugs: Avoid or adjust dosing of NSAIDs, aminoglycosides, or other renal‑impacting medications. - Store at ambient temperature: Keep in original packaging, protect from light and moisture.

Omnipaque may interact with other agents that affect renal function or provoke hypersensitivity.

Major Interactions (Avoid): - Concurrent use of high‑dose NSAIDs or other nephrotoxic drugs that can exacerbate contrast‑induced nephropathy. - Metformin in patients with impaired renal function due to risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers or calcium‑channel blockers that may influence blood pressure responses during injection. - Diuretics, which can alter intravascular volume and affect contrast distribution. - Thyroid hormone replacement, requiring monitoring for iodine‑induced thyroid function changes. - ACE inhibitors or ARBs, which may modify renal hemodynamics and necessitate closer observation. - Radiopharmaceuticals administered in the same session, requiring timing adjustments to avoid image interference.